Drug Interaction Report

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Concomitant use of deuruxolitinib with potent CYP450 3A4 and moderate or potent CYP450 2C9 inducers may significantly decrease the plasma concentrations and therapeutic efficacy of deuruxolitinib. According to the prescribing information, deuruxolitinib is primarily metabolized by CYP450 2C9 (76%) and to a lesser extent by CYP450 3A4 (21%) and 1A2 (3%). Concomitant use of a single dose of deuruxolitinib 12 mg (1.5 times the approved 8 mg dose) with multiple doses of the potent CYP450 3A4 and moderate 2C9 inducer rifampin (600 mg) decreased deuruxolitinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 41% and 78%, respectively.

MANAGEMENT: Use of deuruxolitinib with dual potent CYP450 3A4 and moderate to potent CYP450 2C9 inducers should generally be avoided.

Consumer information for this interaction is not currently available.

MONITOR: Smoking during treatment with deuruxolitinib may increase the risk of major adverse cardiovascular events (MACE) and the risk of developing malignancies. In clinical studies of deuruxolitinib, individuals who were current or former smokers had an additional increased risk of overall malignancies. Also, deuruxolitinib may increase patients' risk of MACE, including myocardial infarction, stroke, and cardiovascular death.

MANAGEMENT: Caution is advised if deuruxolitinib is prescribed to current or past smokers. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur. The manufacturer recommends discontinuing deuruxolitinib in patients that have experienced a myocardial infarction or stroke. Deuruxolitinib may be taken with or without food.